DDInter957 DDInter1578
Iodipamide is a water-soluble radiographic contrast media for cholecystography and intravenous cholangiography.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase (RdRp) enzyme complex for genomic replication, which can be inhibited by a class of drugs known as nucleoside analogues. Remdesivir (GS-5734) is an adenosine triphosphate analogue first described in the literature in 2016 as a potential treatment for Ebola.[A191379, A222393] Broad antiviral activity of remdesivir is suggested by its mechanism of action, and to date, it has demonstrated _in vitro_ activity against the _Arenaviridae_, _Flaviviridae_, _Filoviridae_, _Paramyxoviridae_, _Pneumoviridae_, and _Coronaviridae_ viral families. Remdesivir activity against the _Coronaviridae_ family was first demonstrated in 2017, leading to considerable interest in remdesivir as a possible treatment for COVID-19.[A191427, A198810] Remdesivir was confirmed as a non-obligate chain terminator of RdRp from SARS-CoV-2 and the related SARS-CoV and MERS-CoV, and has been investigated in multiple COVID-19 clinical trials.[L12174, L12177] After initially being granted an FDA Emergency Use Authorization (EUA) on May 1st, 2020, remdesivir was fully approved by the FDA for the treatment of COVID-19 on October 22, 2020. Remdesivir is currently marketed under the trademark name VEKLURY by Gilead Sciences Inc. Remdesivir was also approved by the European Commission on July 3, 2020. Remdesivir in combination with [baricitinib] for the treatment of COVID-19, was granted an FDA Emergency Use Authorization on November 19, 2020.
Iodipamide {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Iodipamide {u} (Compound) is included by {v} (Pharmacologic Class) X-Ray Contrast Activity
X-Ray Contrast Activity {u} (Pharmacologic Class) includes {v} (Compound) Iohexol
Iohexol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Iodipamide {u} (Compound) downregulates {v} (Gene) GRB7
GRB7 {u} (Gene) is downregulated by {v} (Compound) Pazopanib
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Iodipamide {u} (Compound) causes {v} (Side Effect) Body temperature increased
Body temperature increased {u} (Side Effect) is caused by {v} (Compound) Acyclovir
Acyclovir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Iodipamide {u} (Compound) causes {v} (Side Effect) Vomiting
Vomiting {u} (Side Effect) is caused by {v} (Compound) Hydroxychloroquine
Hydroxychloroquine {u} may lead to a major life threatening interaction when taken with {v} Remdesivir
Iodipamide (Compound) binds ALB (Gene) and ALB (Gene) is bound by Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Iodipamide (Compound) is included by X-Ray Contrast Activity (Pharmacologic Class) and X-Ray Contrast Activity (Pharmacologic Class) includes Iohexol (Compound) and Iohexol may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Iodipamide (Compound) downregulates GRB7 (Gene) and GRB7 (Gene) is downregulated by Pazopanib (Compound) and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Iodipamide (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Acyclovir (Compound) and Acyclovir may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Iodipamide (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Hydroxychloroquine (Compound) and Hydroxychloroquine may lead to a major life threatening interaction when taken with Remdesivir